Diacerein

Unassigned

New Medicines

Epidermolysis bullosa simplex

Information

New molecular entity
Castle Creek
Castle Creek

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

First-in-class inhibitor of interleukin-1beta (IL-1g) and production and activity of caspase-1.
Epidermolysis bullosa simplex (EBS) is thought to affect 1 in 17,000 births. Males and females are equally affected [2].
Epidermolysis bullosa simplex
Topical